Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.40 |
| ▸ | DPP4 | P27487 | 5/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 3/20 | 0.35 |
| ▸ | FAP | Q12884 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24067396 | 0.91 | KRAS (0.46) | CNR1DPP9DPP4DPP8HTR6 | |
| SCHEMBL22450844 | 0.84 | TNF (0.52) | TNF | |
| SCHEMBL22450625 | 0.84 | TNF (0.52) | TNF | |
| SCHEMBL24067461 | 0.84 | CNR1 (0.50) | CNR1DPP9DPP4DPP8DPP7 | |
| SCHEMBL24067395 | 0.84 | TNF (0.39) | CNR1KRASTNF | |
| SCHEMBL24182153 | 0.84 | CNR1 (0.42) | CNR1DPP9DPP4DPP8DPP7 | |
| SCHEMBL24182186 | 0.82 | DPP9 (0.43) | CNR1DPP9DPP4DPP8DPP7 | |
| SCHEMBL24067308 | 0.80 | IL1B (0.45) | CNR1HTR6 | |
| SCHEMBL24488651 | 0.79 | TNF (0.39) | CNR1TNF | |
| SCHEMBL24182161 | 0.79 | TNF (0.40) | CNR1HTR6TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| EP-3712162-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BIRC5, XIAP, BIRC2 | CNR1 4767/4885DPP9 226/4885DPP4 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.